Related Experiment Video
Updated: Jul 14, 2026

Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Tosufloxacin tosilate-induced thrombocytopenic purpura
Hideto Takahama1, Hiromi Tazaki
1Department of Dermatology, Nachida Municipal Hospital, Machida, Japan. hdt2taka@rose.ocn.ne.jp
Abstract:
Tosufloxacin tosilate, a member of the naphthyridine group, was developed in Japan and became commercially available in 1990. We experienced a 69-year-old male who developed thrombocytopenic purpura due to tosufloxacin tosilate. The diagnosis was made when similar symptoms (petechiae and thrombocytopenia) were induced by inadvertent challenge with tosufloxacin tosilate. In this paper, we report the first case of tosufloxacin tosilate-induced thrombocytopenic purpura and present a brief published work review.
Related Concept Videos
Toxoplasmosis
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Drug Toxicity: Allergic Reactions
Transient Ischemic Attack l: Introduction
Drug toxicity: Idiosyncratic Reactions
Hypersensitivity Reactions: Cytolytic Reactions
